Kasper Stefan, Hussain Timon, Virchow Isabel, Stuschke Martin, Lang Stephan
Westdeutsches Tumorzentrum, Innere Klinik (Tumorforschung), Universitätsklinikum Essen, Hufelandstraße 55, 45147, Essen, Deutschland.
Westdeutsches Tumorzentrum, Klinik für Hals‑, Nasen- und Ohrenheilkunde, Universitätsklinikum Essen, Essen, Deutschland.
HNO. 2019 Mar;67(3):221-235. doi: 10.1007/s00106-018-0602-6.
Treatment of patients with squamous cell carcinoma of the head and neck (SCCHN) is nowadays multidisciplinary. Therapeutic concepts include modern surgical and radiation techniques as well as systemic therapies. However, the prognosis of these patients is still poor for all stages. In the recurrent or metastatic situation after definitive therapy, there is an indication for palliative systemic treatment, whereby classical platinum-based chemotherapy and the monoclonal epidermal growth factor receptor (EGFR) antibody cetuximab are established, and immunotherapy (IO) has recently been proven a potent treatment option. In this review, the results of trials relevant for approval of checkpoint inhibitors in the palliative setting after platinum failure, as well as ongoing trials evaluating their impact as first-line treatment, in combination with definitive or adjuvant radiation, preoperatively in resectable head and neck cancers, or in combination with other IO therapeutics shall be discussed.
如今，头颈部鳞状细胞癌（SCCHN）患者的治疗是多学科的。治疗理念包括现代外科手术和放疗技术以及全身治疗。然而，这些患者无论处于哪个阶段，预后仍然很差。在确定性治疗后的复发或转移情况下，有姑息性全身治疗的指征，其中经典的铂类化疗和单克隆表皮生长因子受体（EGFR）抗体西妥昔单抗已被确立，并且免疫疗法（IO）最近已被证明是一种有效的治疗选择。在本综述中，将讨论与铂类治疗失败后姑息治疗中检查点抑制剂获批相关的试验结果，以及正在进行的评估其作为一线治疗的影响、与确定性或辅助放疗联合、在可切除的头颈部癌症术前或与其他IO治疗药物联合的试验。
